Merkel Cell Carcinoma Diagnosis and Treatment

Haag, M; Glass, L. Frank; Fenske, Neil A.

doi:10.1111/j.1524-4725.1995.tb00269.x

Cited by 143 publications

(133 citation statements)

References 151 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Meeuwissen et al 3 15 Eleven (21%) of 53 patients suffered locoregional failure, and the 3-year actuarial locoregional control was 75%. In a review of the literature, Haag et al 16 reported that local recurrence developed in 26% to 44% of patients, and during the course of the disease, 55% to 66% of patients developed regional node metastases. Given that 28% of patients had gross disease at either the primary site or the nodes, and 36% had recurrence before registering on the study, these figures compare favorably with those in the literature.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07

Poulsen

Rischin

Walpole

et al. 2003

JCO

201

115

View full text Add to dashboard Cite

Purpose: The effectiveness of synchronous carboplatin, etoposide, and radiation therapy was prospectively assessed in a group of patients with high-risk Merkel cell carcinoma (MCC) of the skin.Patients and Methods: Patients were eligible if they had disease localized to the primary site and nodes, and were required to have at least one of the following high risk features: recurrence after initial therapy, involved nodes, primary tumor size greater than 1 cm, gross residual disease after surgery, or occult primary with nodes. Radiation was delivered to the primary site and nodes to a dose of 50 Gy in 25 fractions over 5 weeks and synchronous carboplatin (area under the curve, 4.5) and intravenous etoposide 80 mg/m 2 days 1 to 3 was given in weeks 1, 4, 7, and 10. The median age of the group was 67 (range, 43-86) years, and there were 39 males and 14 females. Involved nodes (stage II) were present in 33 cases (62%). The sites involved were head and neck (22 patients), occult primary (13 patients), upper limb (eight patients), lower limb (eight patients), and trunk (two patients).Results: Fifty-three patients were entered between 1996 and 2001. The median potential follow-up was 48 months. There were no treatment related deaths. The 3-year overall survival, locoregional control, and distant control were 76%, 75%, and 76%, respectively. Tumor site and the presence of nodes were factors that were predictive for local control and survival. Multivariate analysis indicated that the major factor influencing survival was the presence of nodes; however, this was not a significant factor in locoregional control.Conclusion: High levels of locoregional control and survival have been achieved with the addition of chemotherapy to radiation treatment for high-risk MCC of the skin. The role of chemoradiotherapy for high-risk MCC warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Early reported series quote rates of distant metastatic disease to be 30%, 14,16,17 with some as high as 70%. 8 This does suggest that chemotherapy may have had a positive influence in reducing distant metastatic disease.…”

Section: Discussionmentioning

confidence: 99%

High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07

Poulsen

Rischin

Walpole

et al. 2003

JCO

201

115

View full text Add to dashboard Cite

show abstract

“…It is a highly aggressive skin cancer exhibiting neuroendocrine differentiation (1,2). Although the neoplasm remains infrequent, its incidence is on the rise (3).…”

Section: Introductionmentioning

confidence: 99%

“…Merkel cell carcinoma (MCC) is thought to be issued from Merkel cells (1,2). It is a highly aggressive skin cancer exhibiting neuroendocrine differentiation (1,2).…”

Section: Introductionmentioning

confidence: 99%

Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma

et al. 2006

View full text Add to dashboard Cite

Abstract. Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of 18 FDG PET in the management of MCC. Eleven patients with MCC were examined by 18 FDG PET and PET-CT for staging purpose (n=4) or for detection of recurrence (n=7). Qualitative and quantitative interpretation of PET studies was performed routinely. 18 FDG PET observations were compared to clinical and radiological findings. In 6 patients, PET findings were also compared to histology. In 7 patients, the 18 FDG tumor uptake was compared to the MCC proliferative activity expressed by the Ki-67 index. 18 FDG PET was contributive in 10/11 MCC patients. In 7 patients, 18 FDG PET detected focal lesions or a disseminated stage of the disease including dermal, nodal and visceral metastases. In 3 patients, a normal 18 FDG PET confirmed complete remission of disease. Most MCC patients exhibited highly 18 FDG-avid sites suggestive of increased glucose metabolism. This imaging pattern was related to a high proliferative activity (Ki-67 index >50%). In 1 patient with a weakly proliferative nodal MCC (Ki-67<10%), a false negative result was yielded by metabolic imaging. In 4/11 patients, 18 FDG PET revealed an unsuspected second neoplasm in addition to MCC. It is concluded that whole-body 18 FDG PET may be useful in the management of MCC patients. However, a normal 18 FDG PET aspect cannot rule out MCC with low proliferative activity.

show abstract

“…25 Changes observed on chromosome 1p suggest that 1 or more tumor suppressor genes play a role in the development of MCC, and certain individuals may be predisposed to develop this tumor. 14,20 Deletions involving 1p35-36 are similar to those described for malignant melanoma, pheochromocytoma, and neuroblastoma, tumors known to originate from neural crest cells. 26 Mutations in the tumor protein 73 (p73) gene (p53-like transcription factor) have been observed in MCCs.…”

Section: Etiologymentioning

confidence: 62%

The Merkel cell carcinoma challenge

Bechert

Schnadig

Nawgiri

2012

Cancer Cytopathology

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine carcinoma of the skin that occurs primarily in elderly or immunocompromised patients. For this report, the authors reviewed the diagnostic challenges associated with MCC encountered on their fine-needle aspiration (FNA) service and also conducted an in-depth review of the literature on MCC. A computer search for patients who were diagnosed with MCC by FNA at the authors' institution from 2006 to 2010 was conducted, and 5 patients were selected for cytologic and immunochemical analyses based on their varied and diagnostically challenging clinical presentations. The 5 selected patients had clinical findings commonly associated with MCC, including advanced age (4 of the 5 patients were ages 75-85 years) and a history of previous malignancies (3 of the 5 patients had a history of previous malignancy), and 1 patient was diagnosed with a concomitant low-grade lymphoma.The patients and their disease illustrated the protean clinical presentation of MCC and the clinical and cytologic challenges associated with this neoplasm. The current findings indicate the need for cytopathologists to be aware of the deceptive presentation of this neoplasm and its cytologic and immunochemical features to correctly diagnose this insidious neoplasm.

show abstract

Merkel Cell Carcinoma Diagnosis and Treatment

Cited by 143 publications

References 151 publications

High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07

High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07

Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma

The Merkel cell carcinoma challenge

Contact Info

Product

Resources

About